Drug intelligence / Profile preview

SuperNova

Development stage: Preclinical
Lead developer: Calidi Biotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intramuscular, Intravenous

Overview

SuperNova (CLD-201) is an investigational oncolytic virus therapy being developed by Calidi Biotherapeutics. This program utilizes a vaccinia virus, with plans for an Investigational New Drug (IND) submission in the second half of 2023. The funding for this program was supported by a $3.1 million grant from the California Institute for Regenerative Medicine (CIRM). The name 'SuperNova' is also used for a distinct medical device, a stent-retriever system developed by Gravity Medical Technology, INC, for the treatment of acute ischemic stroke.

Other names: SuperNova-1SuperNova1SuperNova 1

Beyond the preview

Go deeper on SuperNova.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SuperNova.

Explore the full profile